Literature DB >> 23691787

Evaluations of activated clotting time technologies require understanding activating clotting time system differences.

Marcia L Zucker.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 23691787      PMCID: PMC4557466     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


× No keyword cloud information.
  5 in total

1.  Measurement of activated clotting time in children--comparison of the Celite i-STAT ACT with the Medtronic ACT II.

Authors:  M I Hug; S Di Bernardo; F Berger; U Bauersfeld; M Weiss
Journal:  Acta Anaesthesiol Scand       Date:  2004-02       Impact factor: 2.105

2.  Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec ACT and Hemochron Jr apparatus.

Authors:  S Svenmarker; M Appelblad; E Jansson; S Häggmark
Journal:  Perfusion       Date:  2004       Impact factor: 1.972

3.  Predictive performance of three methods of activated clotting time measurement in neonatal ECMO patients.

Authors:  R E Seay; D L Uden; P J Kriesmer; N R Payne
Journal:  ASAIO J       Date:  1993 Jan-Mar       Impact factor: 2.872

4.  Activated clotting time (ACT) testing: analysis of reproducibility.

Authors:  M L Zucker; C Jobes; M Siegel; D Jobes; F M LaDuca
Journal:  J Extra Corpor Technol       Date:  1999-09

5.  Whole blood activated clotting time in infants during extracorporeal membrane oxygenation.

Authors:  T P Green; B Isham-Schopf; R H Steinhorn; C Smith; R J Irmiter
Journal:  Crit Care Med       Date:  1990-05       Impact factor: 7.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.